• BridgeBio Pharma reported that the FDA accepted its New Drug Application with Priority Review for oral infigratinib in achondroplasia and shared Phase 3 data for both infigratinib and BBP-418 that met predefined efficacy endpoints in rare genetic conditions.
• The twin milestones of a priority regulatory review for infigratinib and positive FORTIFY cardiac findings for BBP-418 highlight how BridgeBio Pharma is working to convert its rare disease pipeline into a broader commercial portfolio beyond its existing ATTR-CM franchise.
• The focus now is on how BridgeBio Pharma’s investment narrative could evolve as oral infigratinib progresses through Priority Review.

Scan how BridgeBio Pharma fits into the rare disease opportunity set by…